Authors: Morgan T.¹; Anderson A.²

Source: Clinical Drug Investigation, Volume 22, Number 8, 1 August 2002 , pp. 553-560(8)

Publisher: Adis International

Abstract:

Introduction: A study was undertaken in patients with essential hypertension to compare, by ambulatory blood pressure monitoring, the response to a fixed low dose of perindopril/indapamide with that to irbesartan.

Patients and design: After a 4-week placebo run-in period, 47 patients with a mean ambulatory blood pressure measurement (ABPM) 140mm Hg systolic and/or 90mm Hg diastolic were randomised, double-blind, to perindopril/ indapamide (2/0.625mg; 24 patients) or irbesartan (150mg; 23 patients). Blood pressure normalisation rates were compared using Fisher's exact test and blood pressure decreases using the paired t-test.

Methods: The total duration of the study was 12 weeks. If the clinic blood pressure 8 weeks later was 140/90mm Hg, the dose was doubled. The primary efficacy variable was a final 24-hour ABPM 140/90mm Hg, with a fall in systolic blood pressure 10mm Hg.

Results: More patients (15/23) achieved normalisation taking perindopril/ indapamide than taking irbesartan (7/21) [p < 0.02]. The mean 24-hour systolic and diastolic blood pressure fell by 17 ± 2.3/8 ± 1.3mm Hg (p < 0.001), respectively, in patients taking perindopril/indapamide and by 14 ± 2.9/7 ± 1.6 (p < 0.001), respectively, in patients taking irbesartan. The falls were not significantly different. Systolic and diastolic blood pressure divided into day, night and early morning time periods fell significantly in both groups, but the falls did not differ between treatments. Both treatments were well tolerated and there were no significant adverse biochemical effects.

Conclusion: A fixed low-dose combination of perindopril/indapamide had greater efficacy than irbesartan with a similarly well tolerated adverse effect profile. This makes it a suitable first-line treatment in patients with essential hypertension.

Keywords: Antihypertensives, therapeutic use; Essential hypertension, treatment; Irbesartan, therapeutic use; Perindopril/indapamide, therapeutic use

Document Type: Original article

Affiliations: 1: Department of Physiology, University of Melbourne, Heidelberg, Victoria, Australia 2: Hypertension Clinic, Heidelberg, Victoria, Australia

Publication date: 2002-08-01

Related content

• In this: publication
• By this: publisher
• In this Subject: Pharmacology
• By this author: Morgan T. ;  Anderson A.

Website © Publishing Technology. Article copyright remains with the publisher, society or author(s) as specified within the article.

• Terms and conditions
• Privacy policy
• Information for advertisers